Warfarin-Dose Dx May Not Be Cost-Effective for 'Typical' Patient; May Be for At-Risk Cohort

The meta-analysis comes two weeks before the Centers for Medicare and Medicaid Services is slated to make a national coverage decision regarding PGx-guided warfarin dosing.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.